GrayBug

GrayBug, founded in September 2011, is a spin-off company from the renowned Wilmer Eye Institute at Johns Hopkins University School of Medicine. GrayBug is a clinical-stage biopharmaceutical company focused on developing transformative drugs for chronic retinal and optic nerve diseases. Our novel proprietary technology is designed to release drugs in ocular tissues at a controlled rate for up to 12 months, enhancing patient compliance, reducing healthcare burden, and ultimately providing better clinical outcomes.